3-bromo-2-methylpyrazolo[1,5-a]pyridine | 53902-98-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 3-bromo-2-methylpyrazolo[1,5-a]pyridine
• CAS: 53902-98-0
• 化学式: C₈H₇BrN₂
• 分子量: 211.061
• InChiKey: CNXNUGAFNDHRDX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  17.3
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-bromo-2-methylpyrazolo[1,5-a]pyridine 在 正丁基锂 作用下， 以 四氢呋喃 为溶剂， 以84%的产率得到2-methylpyrazolo<1,5-α>pyridine
  参考文献：
  名称：

  Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083)

  摘要：

  The AAA-ATPase p97 plays vital roles in mechanisms of protein homeostasis, including ubiquitin proteasome system (ups) mediated protein degradation, endoplasmic reticulum-associated degradation (BRAD), and autophagy. Herein we describe our lead optimization efforts focused on in vitro potency, ADME, and pharmaceutical properties that led to the discovery of a potent, ATP-competitive, D2-selective, and orally bioavailable p97 inhibitor 71, CB-6083. Treatment of tumor cells with 71 leads to significant accumulation of markers associated with inhibition of UPS and ERAD functions, which induces irresolvable proteotoxic stress and cell, death. In tumor bearing mice, oral administration of 71 causes rapid accumulation Of markers of the unfolded protein response (UPR) and subsequently induces apoptosis leading to Sustained antitumor activity in in vivo, xenograft models of both solid and hematological tumors. 71 has been taken into phase I clinical trials in patients with multiple myeloma and solid tumors.

  DOI：

  10.1021/acs.jmedchem.5b01346
• 作为产物：
  描述：

  2-甲基-吡唑并[1,5-a]吡啶-3-羧酸乙酯 在 N-溴代丁二酰亚胺(NBS) 、 sodium carbonate 、 sodium hydroxide 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 4.5h， 生成 3-bromo-2-methylpyrazolo[1,5-a]pyridine
  参考文献：
  名称：

  Discovery of a First-in-Class, Potent, Selective, and Orally Bioavailable Inhibitor of the p97 AAA ATPase (CB-5083)

  摘要：

  The AAA-ATPase p97 plays vital roles in mechanisms of protein homeostasis, including ubiquitin proteasome system (ups) mediated protein degradation, endoplasmic reticulum-associated degradation (BRAD), and autophagy. Herein we describe our lead optimization efforts focused on in vitro potency, ADME, and pharmaceutical properties that led to the discovery of a potent, ATP-competitive, D2-selective, and orally bioavailable p97 inhibitor 71, CB-6083. Treatment of tumor cells with 71 leads to significant accumulation of markers associated with inhibition of UPS and ERAD functions, which induces irresolvable proteotoxic stress and cell, death. In tumor bearing mice, oral administration of 71 causes rapid accumulation Of markers of the unfolded protein response (UPR) and subsequently induces apoptosis leading to Sustained antitumor activity in in vivo, xenograft models of both solid and hematological tumors. 71 has been taken into phase I clinical trials in patients with multiple myeloma and solid tumors.

  DOI：

  10.1021/acs.jmedchem.5b01346

文献信息

• [EN] HETEROARYLS AND THEIR USE AS PI3K INHIBITORS<br/>[FR] HÉTÉROARYLES ET APPLICATIONS ASSOCIÉES
  申请人：MILLENNIUM PHARM INC

  公开号：WO2010090716A1

  公开（公告）日：2010-08-12

  This invention provides compounds of formula (IA) or (IB): wherein R1, R2, G1 and HY are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

  这项发明提供了式（IA）或（IB）的化合物：其中R1、R2、G1和HY如规范中所述。这些化合物是PI3K和/或mTor的抑制剂，因此可用于治疗增殖性、炎症性或心血管疾病。
• Heteroaryls and uses thereof
  申请人：Hirose Masaaki

  公开号：US09139589B2

  公开（公告）日：2015-09-22

  This invention provides compounds of formula IA or IB: wherein R1, R2, G1 and HY are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

  本发明提供了公式IA或IB的化合物：其中R1，R2，G1和HY如说明书中所述。这些化合物是PI3K和/或mTor的抑制剂，因此可用于治疗增殖性，炎症性或心血管疾病。
• HETEROARYLS AND THEIR USE AS PI3K INHIBITORS
  申请人：Millennium Pharmaceuticals, Inc.

  公开号：EP2391619A1

  公开（公告）日：2011-12-07
• SUBSTITUTED PYRIDINE AND PYRAZINE BMI-1 INHIBITORS
  申请人：PTC THERAPEUTICS, INC

  公开号：US20160280685A1

  公开（公告）日：2016-09-29

  Amine substituted pyridine and pyrazine compounds and forms thereof that inhibit the function and reduce the level of B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein and methods for their use to inhibit Bmi-1 function and reduce the level of Bmi-1 to treat a cancer mediated by Bmi-1 are described herein.
• US9139589B2
  申请人：——

  公开号：US9139589B2

  公开（公告）日：2015-09-22